Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Read more about Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment.
A non-leaky Artemis-deficient mouse that accurately models the human severe combined immune deficiency phenotype, including resistance to hematopoietic stem cell transplantation. Read more about A non-leaky Artemis-deficient mouse that accurately models the human severe combined immune deficiency phenotype, including resistance to hematopoietic stem cell transplantation.
Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Read more about Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation.
Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Read more about Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia.
Population-based newborn screening for severe combined immunodeficiency. Read more about Population-based newborn screening for severe combined immunodeficiency.
Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases. Read more about Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases.
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Read more about Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia. Read more about Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Read more about Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
